Arcus Biosciences 2023 ASCO Anti-TIGIT Program ARC-7 Results

Arcus Biosciences presents clinical updates on its anti-TIGIT immunotherapy program and ARC-7 results at ASCO 2023. The presentation covers the company's oncology portfolio strategy, collaborative programs with Gilead, and anticipated clinical milestones through 2026. Topics include dominantly developing candidates and the company's first-to-market positioning in immuno-oncology.